86 related articles for article (PubMed ID: 7826082)
1. [Efficacy of combination chemotherapy with mitoxantrone, vincristine, prednisolone (MVP) for recurrence of breast cancer].
Iba T; Yagi Y; Kidokoro A; Fukunaga M; Momose F
Gan To Kagaku Ryoho; 1995 Jan; 22(1):83-6. PubMed ID: 7826082
[TBL] [Abstract][Full Text] [Related]
2. Clinical effects of combination therapy with mitoxantrone, vincristine, and prednisolone in breast cancer.
Katsumata K; Tomioka H; Kusama M; Aoki T; Koyanagi Y
Cancer Chemother Pharmacol; 2003 Jul; 52(1):86-8. PubMed ID: 12764670
[TBL] [Abstract][Full Text] [Related]
3. [Effects of combination chemotherapy M-VEMFH including mitoxantrone in advanced breast cancer].
Ito Y; Hoshino A; Ohara K; Kamiya O; Nagata K; Kojima T; Kinoshita T; Sugiura I
Gan To Kagaku Ryoho; 1985 Oct; 12(10):1999-2003. PubMed ID: 4051516
[TBL] [Abstract][Full Text] [Related]
4. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
Hu WW; Long GD; Stockerl-Goldstein KE; Johnston LJ; Chao NJ; Negrin RS; Blume KG
Clin Cancer Res; 1999 Nov; 5(11):3411-8. PubMed ID: 10589752
[TBL] [Abstract][Full Text] [Related]
5. Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma: a randomized phase II trial.
Hainsworth JD; Jolivet J; Birch R; Hopkins LG; Greco FA
Cancer; 1997 Feb; 79(4):740-8. PubMed ID: 9024712
[TBL] [Abstract][Full Text] [Related]
6. [Efficacy of combination chemotherapy with mitoxantrone, vincristine, doxifluridine and prednisolone for recurrence of breast cancer].
Katsumata K; Yamamoto K; Shibata K; Murano A; Kawasaki M; Moriwaki R; Nagakawa Y; Ogata T; Koyanagi Y; Kusama M
Gan To Kagaku Ryoho; 1997 Dec; 24(15):2227-32. PubMed ID: 9422066
[TBL] [Abstract][Full Text] [Related]
7. [Results of clinical trials with a CMitF (cyclophosphamide, mitoxantrone, and 5-fluorouracil) regimen versus a CAF (cyclophosphamide, adriamycin, and 5-fluorouracil) regimen in advanced/relapsed breast cancer].
Taguchi T; Sakai K; Terasawa T; Wada H
Gan To Kagaku Ryoho; 1986 Sep; 13(9):2820-8. PubMed ID: 3530139
[TBL] [Abstract][Full Text] [Related]
8. Mitoxantrone combined with vincristine, cyclophosphamide and fluorouracil for advanced breast cancer. A study of short-term response rate.
Misset JL; Metz R; Gil-Delgado M; Keiling R; Cappelaere P; Armand JP; Prévot G; Grimbert J; Mathé G; Hibberd M
Anticancer Res; 1987; 7(4B):737-40. PubMed ID: 3674760
[TBL] [Abstract][Full Text] [Related]
9. A phase III randomized trial comparing adjuvant concomitant chemoradiotherapy versus standard adjuvant chemotherapy followed by radiotherapy in operable node-positive breast cancer: final results.
Rouëssé J; de la Lande B; Bertheault-Cvitkovic F; Serin D; Graïc Y; Combe M; Leduc B; Lucas V; Demange L; Nguyen TD; Castèra D; Krzisch C; Villet R; Mouret-Fourme E; Garbay JR; Noguès C;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1072-80. PubMed ID: 16504757
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel with mitoxantrone with or without 5-fluorouracil and high-dose leucovorin in the treatment of metastatic breast cancer.
Greco FA; Hainsworth JD
Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-61-S17-64. PubMed ID: 9374096
[TBL] [Abstract][Full Text] [Related]
11. Mitoxantrone, 5-fluorouracil and cyclophosphamide in advanced breast cancer.
Martoni A; Rani P; Ercolino L; Canova N; Pannuti F
Chemioterapia; 1988 Oct; 7(5):345-9. PubMed ID: 3224403
[TBL] [Abstract][Full Text] [Related]
12. Mitoxantrone and cyclophosphamide in patients with advanced breast cancer.
Ehninger G; Weible KH; Heidemann EG; Waller HD
Cancer Treat Rep; 1984 Oct; 68(10):1283-4. PubMed ID: 6525600
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.
Rivkin SE; Green SJ; Lew D; Costanzi JJ; Athens JW; Osborne CK; Vaughn CB; Martino S
Cancer; 2003 Jan; 97(1):21-9. PubMed ID: 12491501
[TBL] [Abstract][Full Text] [Related]
14. [Combined chemoendocrine therapy using adriamycin, cyclophosphamide and high dose toremifene in patients with recurrent breast cancer].
Wada N; Kobayashi H; Oka S; Ando J; Tamura H
Gan To Kagaku Ryoho; 2002 Nov; 29(11):1935-42. PubMed ID: 12465393
[TBL] [Abstract][Full Text] [Related]
15. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
16. Phase I/II study with paclitaxel in combination with weekly high-dose 5-fluorouracil/folinic acid in the treatment of metastatic breast cancer: an interim analysis.
Klaassen U; Wilke H; Pari CP; Strumberg D; Harstrick A; Eberhardt W; Becher R; Diergarten K; Seeber S
Semin Oncol; 1995 Dec; 22(6 Suppl 14):7-11. PubMed ID: 8553083
[TBL] [Abstract][Full Text] [Related]
17. [Effects of DAC (doxifluridine, adriamycin, cyclophosphamide) chemotherapy in advanced breast cancer patients].
Tashiro H; Takahashi I; Yamamura S; Ishikawa T; Yanaga K; Wakasugi K; Matsusaka T; Kume K
Gan To Kagaku Ryoho; 1999 May; 26(6):775-9. PubMed ID: 10410146
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel and 5-fluorouracil in metastatic breast cancer: the US experience.
Paul DM; Garrett AM; Meshad M; DeVore RD; Porter LL; Johnson DH
Semin Oncol; 1996 Feb; 23(1 Suppl 1):48-52. PubMed ID: 8629038
[TBL] [Abstract][Full Text] [Related]
19. [A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant setting].
Inaji H; Sakai K; Oka T; Ozawa K; Saito Y; Senoo T; Taguchi T; Terasawa T; Nakao K; Mori T; Koyama H; Oshima A
Gan To Kagaku Ryoho; 2006 Oct; 33(10):1423-9. PubMed ID: 17033231
[TBL] [Abstract][Full Text] [Related]
20. [The feasibility of CEF (cyclophosphamide, epirubicin, 5-FU) regimen in the adjuvant setting of primary breast cancer].
Honda S; Toi M; Shimizu S; Hayashi K; Tominaga T
Gan To Kagaku Ryoho; 1997 Apr; 24(6):679-83. PubMed ID: 9126304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
